ArticleScientific reports2025
Identification and experimental validation of biomarkers associated with macrophages in myocardial ischemia-reperfusion injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Myocardial ischemia-reperfusion injury (MIRI) is a complex process leading to substantial myocardial damage. Macrophages play a pivotal role in tissue development and homeostasis. This study aimed to identify macrophage-associated biomarkers in MIRI and explore the molecular mechanisms underlying their involvement. Macrophage-related genes (MRGs) were retrieved from public databases, and differentially expressed genes (DEGs) were identified using transcriptomic data. MRGs and DEGs were integrated to identify candidate genes. Biomarkers were identified through protein-protein interaction (PPI) analysis and gene expression validation. Enrichment analysis, immune infiltration analysis, construction of molecular regulatory networks, drug prediction, and molecular docking were conducted to investigate the functional mechanisms of the identified biomarkers. Additionally, reverse transcription quantitative polymerase chain reaction (RT-qPCR) was performed. Finally, single-cell data were analyzed to assess the distribution of biomarkers across annotated cell types. Tlr7, Tlr1, Tlr6, and Il33 were identified as key biomarkers. Enrichment analysis revealed that the "Ribosome," "Oxidative phosphorylation," and "Spliceosome" pathways were significantly enriched in these biomarkers. Immune infiltration analysis demonstrated distinct differences in the presence of macrophages, M1 macrophages, and M2 macrophages between MIRI and control groups. Notably, Tlr7, Tlr1, and Tlr6 exhibited strong positive correlations with macrophages, M1, and M2 macrophages. Biomarkers were regulated by several transcription factors (TFs) (e.g., MYC, TBP) and microRNAs (miRNAs) (e.g., -mmu-miR-15a-5p). Drug prediction and molecular docking analyses indicated that IMIQUIMOD and Acetaminophen might serve as potential therapeutic targets for MIRI. RT-qPCR confirmed significant upregulation of Tlr7, Tlr1, and Tlr6 in the MIRI group, consistent with bioinformatics findings, whereas Il33 showed no significant difference between the two groups. Five major cell types were identified, including pericytes, M2 macrophages, and M1 macrophages. Notably, Tlr7 and Tlr1 were predominantly expressed in M2 macrophages. Tlr7, Tlr1, Tlr6, and Il33 were identified as macrophage-associated biomarkers in MIRI, providing valuable insights for MIRI diagnosis and potential therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.